المؤلفون: Sorger, Joel, Hawkins, Douglas, Spunt, Sheri, Wang, Dian, Million, Lynn, Terezakis, Stephanie, Choy, Edwin, Okuno, Scott, Venkatramani, Rajkumar, Chen, Yen-Lin, Scharschmidt, Thomas, Kayton, Mark, Weiss, Aaron, Xue, Wei, Binitie, Odion, Hayes Dixon, Andrea, Randall, R

المصدر: Seminars in Surgical Oncology. 127(5)

مصطلحات موضوعية: neoadjuvant, pazopanib, sarcoma, wound complications, wound healing, Child, Humans, Neoadjuvant Therapy, Postoperative Complications, Pyrimidines, Sarcoma, Soft Tissue Neoplasms

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/63x1497zTest

المؤلفون: Jin-Ju Lei, Jie Rao, Hong-Yan Feng, De-Dong Cao, Hong-Lin Yan, Jing-Ping Yuan, Zhen-Min Jiang, Yi-Qiao Zhang

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: metastatic thyroid-like follicular carcinoma of the kidney, ATM and POLE mutations, programmed death 1 receptor inhibitor, pazopanib, radiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1352865/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/9ee003391797481b8be2355ebd534d8bTest

المؤلفون: Gupta, Amit¹, Dahima, Rashmi

المصدر: Research Journal of Pharmacy and Technology 16(8):3561-3568. 2023

المؤلفون: Mishra, Ramendu¹, Devi, Anjana

المصدر: Research Journal of Pharmacy and Technology 16(8):3633-3637. 2023

المؤلفون: Minyue Zhang, Fei Xiao, Jianchen Fang, Zebing Liu, Yanying Shen, Di Zhu, Yiwei Zhang, Jian Hou, Honghui Huang

المصدر: International Journal of Molecular Sciences, Vol 25, Iss 13, p 7293 (2024)

مصطلحات موضوعية: histiocytic sarcoma, follicular lymphoma, immune-targeted therapy, Daratumumab, Pazopanib, Tislelizumab, Biology (General), QH301-705.5, Chemistry, QD1-999

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1422-0067/25/13/7293Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test

الوصول الحر: https://doaj.org/article/0afc90a7fcc94335a0e0eb1c3536e591Test

المؤلفون: Ke Wang, Pei-Yin Liao, Wei-Chun Chang, Cian-Ru Yang, Yu-Ting Su, Ping-Ching Wu, Yang-Chang Wu, Yao-Ching Hung, Najim Akhtar, Hsueh-Chou Lai, Wen-Lung Ma

المصدر: Frontiers in Pharmacology, Vol 14 (2024)

مصطلحات موضوعية: hepatocellular carcinoma, LDC, linoleate, pazopanib, LAPC, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1281067/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/c84b74d970bd4b2997ab62852ef8f6dfTest

المؤلفون: A. A. Rumyantsev, А. А. Румянцев

المصدر: Meditsinskiy sovet = Medical Council; № 22 (2023); 80-86 ; Медицинский Совет; № 22 (2023); 80-86 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ниволумаб, IMDC, MSKCC, favourable prognosis, sunitinib, pazopanib, pembrolizumab, axitinib, lenvatinib, cabozantinib, nivolumab, благоприятный прогноз, сунитиниб, пазопаниб, пембролизумаб, акситиниб, ленватиниб, кабозантиниб

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7983/7070Test; Piao X-M, Byun YJ, Zheng C-M, Song SJ, Kang HW, Kim WT et al. A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC. Cancers. 2023;15(3):935. https://doi.org/10.3390/cancers15030935Test.; Волкова МИ, Алексеев БЯ, Гладков ОА, Матвеев ВБ, Носов ДА. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли. 2022;12(3s2-1):579–588. https://doi.org/10.18027/2224-5057-2022-12-3s2-579-588Test.; Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ et al. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2022;40(25):2957–2995. https://doi.org/10.1200/JCO.22.00868Test.; Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82(4):399–410. https://doi.org/10.1016/j.eururo.2022.03.006Test.; Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19(3):405–415. https://doi.org/10.1016/S1470-2045Test(18)30081-0.; Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116–1127. https://doi.org/10.1056/NEJMoa1816714Test.; Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol. 2023;41(17 Suppl.):LBA4501. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501Test.; Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563–1573. https://doi.org/10.1016/S1470-2045Test(20)30436-8.; Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study. Eur Urol. 2023;84(5):449–454. https://doi.org/10.1016/j.eururo.2023.06.006Test.; Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncol. 2019;15(9):929–941. https://doi.org/10.2217/fon-2018-0745Test.; Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021;384(14):1289–1300. https://doi.org/10.1056/NEJMoa2035716Test.; Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228–238. https://doi.org/10.1016/S1470-2045Test(23)00049-9.; Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2023;41(16 Suppl.):4502. https://doi.org/10.1200/JCO.2023.41.16_suppl.4502Test.; Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M et al. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. Eur Urol Oncol. 2023;6(4):437–446. https://doi.org/10.1016/j.euo.2023.01.010Test.; Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023;13:1223282. https://doi.org/10.3389/fonc.2023.1223282Test.; Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047Test.; Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039. https://doi.org/10.1016/j.annonc.2020.04.010Test.; Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB et al. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023;8(3):101210. https://doi.org/10.1016/j.esmoop.2023.101210Test.; Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021;384(9):829–841. https://doi.org/10.1056/NEJMoa2026982Test.; Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888–898. https://doi.org/10.1016/S1470-2045Test(22)00290-X.; Burotto M, Powles T, Escudier B, Apolo AB, Bourlon MT, Shah AY et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. J Clin Oncol. 2023;41(6 Suppl.):603. https://doi.org/10.1200/JCO.2023.41.6_suppl.603Test.; Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol. 2022;32(1):61–68. https://doi.org/10.1097/MOU.0000000000000940Test.; Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy. 2022;14(2):145–153. https://doi.org/10.2217/imt-2021-0157Test.; Hou M, Xing H, He S, Yang X, Peng D, Li Y et al. The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. J Oncol. 2022;2022:7733251. https://doi.org/10.1155/2022/7733251Test.; Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E et al. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;5(5):CD013798. https://doi.org/10.1002/14651858.CD013798.pub2Test.; Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata D et al. The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer. BMC Cancer. 2012;12(1):598. https://doi.org/10.1186/1471-2407-12-598Test.; Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023;24(3):213–227. https://doi.org/10.1016/S1470-2045Test(22)00793-8.; Parikh M, Lara PN. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer. 2022;6(2):105–107. https://doi.org/10.3233/KCA-229003Test.; Tzeng A, Tzeng TH, Ornstein MC. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer. 2021;9(10):e003473. https://doi.org/10.1136/jitc-2021-003473Test.; https://www.med-sovet.pro/jour/article/view/7983Test

الإتاحة: https://doi.org/10.21518/ms2023-419Test
https://doi.org/10.3390/cancers15030935Test
https://doi.org/10.18027/2224-5057-2022-12-3s2-579-588Test
https://doi.org/10.1200/JCO.22.00868Test
https://doi.org/10.1016/j.eururo.2022.03.006Test
https://doi.org/10.1016/S1470-2045Test(18)30081-0
https://doi.org/10.1056/NEJMoa1816714Test
https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4501Test
https://doi.org/10.1016/S1470-2045Test(20)30436-8
https://doi.org/10.1016/j.eururo.2023.06.006Test

المؤلفون: Chien-Pin Lai, Yong-Syuan Chen, Tsung-Ho Ying, Cheng-Yen Kao, Hui-Ling Chiou, Shao-Hsuan Kao, Yi-Hsien Hsieh

المصدر: Kidney Research and Clinical Practice, Vol 42, Iss 4, Pp 487-500 (2023)

مصطلحات موضوعية: apoptosis, autophagy, melatonin, pazopanib, renal cell carcinoma, Internal medicine, RC31-1245, Specialties of internal medicine, RC581-951

وصف الملف: electronic resource

العلاقة: http://www.krcp-ksn.org/upload/pdf/j-krcp-22-114.pdfTest; https://doaj.org/toc/2211-9132Test; https://doaj.org/toc/2211-9140Test

الوصول الحر: https://doaj.org/article/5f79812f1db14b8bbd7fedc7f2a628aeTest

المؤلفون: Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee, U-Syn Ha

المصدر: BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)

مصطلحات موضوعية: Renal cell carcinoma, Sunitinib, Pazopanib, Axitinib, Cabozantinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/80501d8af65a4ea2a9ed4a7b9c6e2092Test

المؤلفون: Akihiro Ohmoto, Aya Ebihara, Junichi Tomomatsu, Kenji Nakano, Makiko Ono, Masatoshi Nishizawa, Mayu Yunokawa, Naoki Fukuda, Shunji Takahashi, Takuya Oyakawa, Taro Shiga, Tsuya Urasaki, Xiaofei Wang, Yasuyoshi Sato

المصدر: Circulation Journal. 2024, 88(2):228